NASDAQ:CHMA Chiasma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chiasma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.53 -0.40 (-8.11 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$4.51Now: $4.53▼$4.9550-Day Range$4.44MA: $5.04▼$5.5052-Week Range$2.88Now: $4.53▼$7.75Volume391,177 shsAverage Volume465,389 shsMarket Capitalization$261.83 millionP/E RatioN/ADividend YieldN/ABeta1.62 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingChiasma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.33, Chiasma has a forecasted upside of 172.3% from its current price of $4.53.Amount of Analyst CoverageChiasma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesChiasma has received 251 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChiasma has received 258 “underperform” votes. (Add your “underperform” vote.)Community SentimentChiasma has received 50.69% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote “Outperform” if you believe CHMA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChiasma does not currently pay a dividend.Dividend GrowthChiasma does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chiasma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Chiasma is held by insiders.Percentage Held by Institutions52.40% of the stock of Chiasma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chiasma are expected to grow in the coming year, from ($1.66) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chiasma is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chiasma is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChiasma has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHMA Previous Symbol CUSIPN/A CIK1339469 Webwww.chiasmapharma.com Phone617-928-5300Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio4.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book2.22Profitability EPS (Most Recent Fiscal Year)($1.06) Net Income$-36,320,000.00 Net MarginsN/A Return on Equity-73.47% Return on Assets-58.22%Miscellaneous Employees49 Outstanding Shares57,800,000Market Cap$261.83 million Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $4.53 -0.40 (-8.11 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CHMA News and Ratings via Email Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Chiasma (NASDAQ:CHMA) Frequently Asked Questions How has Chiasma's stock price been impacted by Coronavirus (COVID-19)? Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CHMA shares have increased by 15.6% and is now trading at $4.53. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Chiasma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chiasma. When is Chiasma's next earnings date? Chiasma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Chiasma. How were Chiasma's earnings last quarter? Chiasma Inc (NASDAQ:CHMA) posted its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.10. View Chiasma's earnings history. What price target have analysts set for CHMA? 4 equities research analysts have issued 12 month price targets for Chiasma's stock. Their forecasts range from $8.00 to $19.00. On average, they anticipate Chiasma's share price to reach $12.33 in the next year. This suggests a possible upside of 172.3% from the stock's current price. View analysts' price targets for Chiasma. Are investors shorting Chiasma? Chiasma saw a decline in short interest in the month of August. As of August 14th, there was short interest totaling 1,780,000 shares, a decline of 16.8% from the July 30th total of 2,140,000 shares. Based on an average daily trading volume, of 791,200 shares, the days-to-cover ratio is presently 2.2 days. View Chiasma's Short Interest. Who are some of Chiasma's key competitors? Some companies that are related to Chiasma include Akero Therapeutics (AKRO), Passage Bio (ZNTL), Rhythm Pharmaceuticals (RYTM), Stoke Therapeutics (STOK), Innoviva (INVA), Karyopharm Therapeutics (KPTI), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), NGM Biopharmaceuticals (NGM), Kiniksa Pharmaceuticals (KNSA), Nkarta (NKTX), Athenex (ATNX), Legend Biotech (AMTI), Zogenix (ZGNX) and Theravance Biopharma (TBPH). View all competitors. What other stocks do shareholders of Chiasma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Amarin (AMRN), Alnylam Pharmaceuticals (ALNY) and Exelixis (EXEL). Who are Chiasma's key executives? Chiasma's management team includes the following people: Mr. Raj Kannan, CEO & Director (Age 56, Pay $475.78k)Mr. Mark J. Fitzpatrick, Pres (Age 57, Pay $788.3k)Mr. Lee Giguere, VP & Gen. Counsel (Age 40, Pay $134.52k)Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 55, Pay $520.92k)Mr. Drew Enamait, VP of Fin. & Admin. (Age 46) When did Chiasma IPO? (CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers. What is Chiasma's stock symbol? Chiasma trades on the NASDAQ under the ticker symbol "CHMA." Who are Chiasma's major shareholders? Chiasma's stock is owned by many different retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (3.88%), Ikarian Capital LLC (3.38%), FMR LLC (3.33%), FMR LLC (2.44%), Nuveen Asset Management LLC (0.72%) and Driehaus Capital Management LLC (0.41%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam. View institutional ownership trends for Chiasma. Which major investors are selling Chiasma stock? CHMA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, FMR LLC, FMR LLC, UBS Group AG, Goldman Sachs Group Inc., and WINTON GROUP Ltd. View insider buying and selling activity for Chiasma. Which major investors are buying Chiasma stock? CHMA stock was bought by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., Nuveen Asset Management LLC, California Public Employees Retirement System, Bessemer Group Inc., Marshall Wace LLP, and Virtu Financial LLC. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Raj Kannan, Scott Minick, and William Ludlam. View insider buying and selling activity for Chiasma. How do I buy shares of Chiasma? Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Chiasma's stock price today? One share of CHMA stock can currently be purchased for approximately $4.53. How big of a company is Chiasma? Chiasma has a market capitalization of $261.83 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe. What is Chiasma's official website? The official website for Chiasma is www.chiasmapharma.com. How can I contact Chiasma? Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
